Corpus coverage

319,975 slides

319,974 are described (100%), so the treemap can explain the corpus instead of just counting files.

Total slides
319,975
Described
319,974
Pending
1

Slide type composition

dynamicclickable
Slide type

Showing 319,974 described slides — 100.0% of 319,975 rendered pages

Tile area is proportional to slide count. Click a category to open its subtype map.

all document kinds · all orientations

Slide collection

223,921-223,950 of 319,975

filter-aware
06
Includes a B-cell development diagram and a human anatomy map linking specific diseases to medical specialties.Immix Biopharma | Investor Presentation Deck | 62 slides · ImmixBio
Pitch deck Investor relations Beat · Problem & Complication1 hit
07
The slide uses a hub-and-spoke diagram to connect a central problem (CAR-T Neurotoxicity) to four specific negative outcomes.Immix Biopharma | Investor Presentation Deck | 62 slides · ImmixBio
Pitch deck Investor relations Beat · Problem & Complication1 hit
08
The slide uses a structural diagram to highlight the substitution of the 'Tumor Binding Domain' with the 'COBRA Binder' in the NXC-201 molecule.Immix Biopharma | Investor Presentation Deck | 62 slides · ImmixBio
Pitch deck Investor relations Beat · Problem & Complication1 hit
09
The slide uses a diagram to map specific protein domains to their functional benefits.Immix Biopharma | Investor Presentation Deck | 62 slides · ImmixBio
Pitch deck Investor relations Beat · Problem & Complication1 hit
10
The slide uses external citations from Nature Medicine and Signal Transduction and Targeted Therapy to validate the scientific approach of ITAM modification.Immix Biopharma | Investor Presentation Deck | 62 slides · ImmixBio
Pitch deck Investor relations Beat · Problem & Complication1 hit
11
The slide uses a combination of bar charts for preclinical cytokine release and a table for clinical outcomes to demonstrate the superiority of the NXC-201 CD8 hinge optimization.Immix Biopharma | Investor Presentation Deck | 62 slides · ImmixBio
Pitch deck Investor relations Beat · Problem & Complication1 hit
12
Includes a scientific quote justifying the use of Glycine/Serine linkers.Immix Biopharma | Investor Presentation Deck | 62 slides · ImmixBio
Pitch deck Investor relations Beat · Problem & Complication1 hit
13
The slide uses a hub-and-spoke diagram to highlight four key clinical outcomes.Immix Biopharma | Investor Presentation Deck | 62 slides · ImmixBio
Pitch deck Investor relations Beat · Problem & Complication1 hit
14
The slide explicitly notes that these are not head-to-head results and caution should be exercised in comparison.Immix Biopharma | Investor Presentation Deck | 62 slides · ImmixBio
Pitch deck Investor relations Beat · Problem & Complication1 hit
15
The slide uses a biological diagram to illustrate the structural difference of the N-GENIUS platform compared to competitors like Abecma and Carvykti.Immix Biopharma | Investor Presentation Deck | 62 slides · ImmixBio
Pitch deck Investor relations Beat · Evidence & Proof1 hit
16
Includes comparative data points for transduction efficiency and experimental data for tonic signaling and anti-exhaustion.Immix Biopharma | Investor Presentation Deck | 62 slides · ImmixBio
Pitch deck Investor relations Beat · Evidence & Proof1 hit
17
The slide uses a visual timeline comparison to highlight the clinical advantage of NXC-201's shorter side-effect profile.Immix Biopharma | Investor Presentation Deck | 62 slides · ImmixBio
Pitch deck Investor relations Beat · Evidence & Proof1 hit
18
The chart demonstrates a clear inverse relationship where the spike in HBI0101 cells corresponds to a rapid decline in dFLC levels, stabilizing around the 30-day mark.Immix Biopharma | Investor Presentation Deck | 62 slides · ImmixBio
Pitch deck Investor relations Beat · Evidence & Proof1 hit
19
The slide uses a bottom-up summation approach to define the total eligible patient pool.Immix Biopharma | Investor Presentation Deck | 62 slides · ImmixBio
Pitch deck Investor relations Beat · Evidence & Proof1 hit
20
The slide uses a causal chain to link cellular pathology to systemic organ damage.Immix Biopharma | Investor Presentation Deck | 62 slides · ImmixBio
Pitch deck Investor relations Beat · Evidence & ProofLoop · Cost Of Inaction1 hit
21
The slide uses a bar chart to compare hematologic and cardiac response rates across different therapies.Immix Biopharma | Investor Presentation Deck | 62 slides · ImmixBio
Pitch deck Investor relations Beat · Evidence & ProofLoop · Cost Of Inaction1 hit
22
The slide uses a table structure to contrast patient segments and includes a bar chart visualization for patient growth.Immix Biopharma | Investor Presentation Deck | 62 slides · ImmixBio
Pitch deck Investor relations Beat · Evidence & ProofLoop · Cost Of Inaction1 hit
23
The slide explicitly notes that these are cross-trial comparisons and not head-to-head results.Immix Biopharma | Investor Presentation Deck | 62 slides · ImmixBio
Pitch deck Investor relations Beat · Evidence & ProofLoop · Cost Of Inaction1 hit
24
Includes a footnote citing FDA approval precedents for similar single-arm studies.Immix Biopharma | Investor Presentation Deck | 62 slides · ImmixBio
Pitch deck Investor relations Beat · Evidence & ProofLoop · Cost Of Inaction1 hit
25
Uses a visual icon-grid to represent market expansion.Immix Biopharma | Investor Presentation Deck | 62 slides · ImmixBio
Pitch deck Investor relations Beat · Evidence & ProofLoop · Cost Of Inaction1 hit
26
Includes detailed clinical trial citations in the footer.Immix Biopharma | Investor Presentation Deck | 62 slides · ImmixBio
Pitch deck Investor relations Beat · Evidence & ProofLoop · Cost Of Inaction1 hit
27
The slide uses a two-column layout to separate milestones by drug candidate.Immix Biopharma | Investor Presentation Deck | 62 slides · ImmixBio
Pitch deck Investor relations Beat · Evidence & ProofLoop · Cost Of Inaction1 hit
28
The slide uses a standard pharmaceutical pipeline table format.Immix Biopharma | Investor Presentation Deck | 62 slides · ImmixBio
Pitch deck Investor relations Beat · Evidence & ProofLoop · Cost Of Inaction1 hit
29
Includes a comparative table of clinical outcomes (ORR/CR) for NXC-201 vs. Allogeneic CAR-T and Bispecifics.Immix Biopharma | Investor Presentation Deck | 62 slides · ImmixBio
Pitch deck Investor relations Beat · Evidence & ProofLoop · Cost Of Inaction1 hit
30
The slide uses a stylized area chart to represent market segments and their respective valuations.Immix Biopharma | Investor Presentation Deck | 62 slides · ImmixBio
Pitch deck Investor relations Beat · Evidence & ProofLoop · Cost Of Inaction1 hit
31
The slide uses a red dashed box to highlight the primary efficacy metrics for comparison.Immix Biopharma | Investor Presentation Deck | 62 slides · ImmixBio
Pitch deck Investor relations Beat · Evidence & ProofLoop · David Goliath1 hit
32
The table uses a cross-trial comparison format. The red dashed box highlights the key clinical data rows.Immix Biopharma | Investor Presentation Deck | 62 slides · ImmixBio
Pitch deck Investor relations Beat · Evidence & ProofLoop · David Goliath1 hit
33
The chart uses a grouped bar structure to compare NXC-201 (green) against other therapies (blue/red/grey).Immix Biopharma | Investor Presentation Deck | 62 slides · ImmixBio
Pitch deck Investor relations Beat · Evidence & ProofLoop · David Goliath1 hit
34
The slide uses a side-by-side comparison of two disease indications, each with a list of clinical outcomes and a bottom section showing relevant market competitors and patient incidence numbers.Immix Biopharma | Investor Presentation Deck | 62 slides · ImmixBio
Pitch deck Investor relations Beat · Evidence & Proof1 hit
35
The chart illustrates clinical trial efficacy data for NXC-201.Immix Biopharma | Investor Presentation Deck | 62 slides · ImmixBio
Pitch deck Investor relations Beat · Impact & Next Steps1 hit